O
RVNC

OrbiMed’s Revance Therapeutics, Inc. RVNC Stock Holding History

OrbiMed’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100,000
Closed -$2.53M – 143
2023
Q2 		$2.53M Buy
100,000
+50,000
+100% +$1.56M 0.05% 112
2023
Q1 		$1.61M Buy
+50,000
New +$1.56M 0.03% 114

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed's RVNC Position: Q3 2023 in Review

OrbiMed sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 100,000 shares — an estimated $2.53M sold.

OrbiMed first reported a position in RVNC in Q1 2023 and held it in 2 quarters. The position peaked at $2.53M in Q2 2023. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

  • OrbiMed reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
  • OrbiMed sold 100,000 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $2.53M.
  • OrbiMed first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 2 quarters.
  • OrbiMed's Revance Therapeutics, Inc. position peaked at $2.53M in Q2 2023.
  • 186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on OrbiMed's 13F filing for Q3 2023, filed 14 Nov 2023.